89549
Tobramycin
≥99.0% (TLC)
别名:
Nebramycin Factor 6, O-[3-Amino-3-deoxy-α-D-glucopyranosyl-(1→6)]-O-[2,6-diamino-2,3,6-trideoxy-α-D-ribohexopyranosyl-(1→4)]-2-deoxy-D-streptamine
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H37N5O9
化学文摘社编号:
分子量:
467.51
EC Number:
251-322-5
UNSPSC Code:
51101500
MDL number:
Beilstein/REAXYS Number:
1357507
InChI
1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1
InChI key
NLVFBUXFDBBNBW-SNGYORCQSA-N
SMILES string
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
assay
≥99.0% (TLC)
impurities
≤8% water
solubility
H2O: 50 mg/mL, clear, faintly yellow
mode of action
protein synthesis | interferes
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
General description
Chemical structure: aminoglycoside
Biochem/physiol Actions
Tobramycin is an aminoglycoside.
Mode of Action: Binds to 70S ribosomal subunit; inhibits translocation; elicits miscoding.
Spectrum of Activity: Gram negative bacteria. Not effective against Enterococci.
Mode of Action: Binds to 70S ribosomal subunit; inhibits translocation; elicits miscoding.
Spectrum of Activity: Gram negative bacteria. Not effective against Enterococci.
法规信息
涉药品监管产品
此项目有
Catherine G Ambrose et al.
The Journal of bone and joint surgery. American volume, 96(2), 128-134 (2014-01-17)
Prevention of infection associated with uncemented orthopaedic implants could lead to improved implant stability and better patient outcomes. We hypothesized that coating porous metal implants with antibiotic-containing microspheres would prevent infections in grossly contaminated wounds. Bioresorbable polymer microspheres containing tobramycin
Yifat Berkov-Zrihen et al.
Organic letters, 15(24), 6144-6147 (2013-11-15)
A short site-selective strategy for the activation and derivatization of alcohols of the clinically important aminoglycoside tobramycin is reported. The choice of amine protecting group affected the site-selective conversion of secondary alcohols of tobramycin into leaving groups. Temperature-dependent, chemoselective sequential
Stefanie Hennig et al.
Clinical pharmacokinetics, 52(4), 289-301 (2013-02-20)
While several studies have examined the pharmacokinetics of tobramycin in patients with cystic fibrosis (CF), there is no consensus on whether they differ in patients with and without CF. The objectives of this study were to identify covariates which explain
Namrata Sharma et al.
Ophthalmology, 120(6), 1173-1178 (2013-02-19)
To compare the equivalence of moxifloxacin 0.5% with a combination of fortified cefazolin sodium 5% and tobramycin sulfate 1.3% eye drops in the treatment of moderate bacterial corneal ulcers. Randomized, controlled, equivalence clinical trial. Microbiologically proven cases of bacterial corneal
Heleen Van Acker et al.
PloS one, 8(3), e58943-e58943 (2013-03-22)
The presence of persister cells has been proposed as a factor in biofilm resilience. In the present study we investigated whether persister cells are present in Burkholderia cepacia complex (Bcc) biofilms, what the molecular basis of antimicrobial tolerance in Bcc
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持